Institut Català de la Salut
[Palma-Álvarez RF, Ros-Cucurull E, Daigre C, Ramos-Quiroga JA, Grau-López L] Servei de Psiquiatria, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Departament de Psiquiatria i Medicina Legal, Universitat Autònoma de Barcelona, Bellaterra, Spain. Group of Psychiatry, Mental Health and Addiction, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Biomedical Network Research Centre on Mental Health (CIBERSAM), Barcelona, Spain. [Perea-Ortueta M] Servei de Psiquiatria, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Group of Psychiatry, Mental Health and Addiction, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Serrano-Pérez P] Servei de Psiquiatria, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Departament de Psiquiatria i Medicina Legal, Universitat Autònoma de Barcelona, Bellaterra, Spain. Group of Psychiatry, Mental Health and Addiction, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Martínez-Luna N, Salas-Martínez A] Servei de Psiquiatria, Vall d'Hebron Hospital Universitari, Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2021-06-15T12:34:35Z
2021-06-15T12:34:35Z
2021-04-09
Alexitimia; Qualitat de vida relacionada amb la salut; Trastorn per consum de substàncies
Alexitimia; Calidad de vida relacionada con la salud; Trastorno por uso de sustancias
Alexithymia; Health-related quality of life; Substance use disorder
Background: Alexithymia frequently correlates with several psychiatric disorders, including substance use disorder (SUD). However, most studies reporting the associations between alexithymia and psychiatric disorders have been performed in populations without SUD. This research, therefore, evaluates alexithymia in Spanish patients with SUD and the relationship among alexithymia, psychiatric comorbidities, psychological symptoms/traits, SUD variables, and health-related quality of life (HRQoL). Methodology: A cross-sectional study was conducted with 126 Spanish outpatients with SUD (75.4% males; mean age 43.72 ± 14.61 years), correlating their alexithymia levels (using the Toronto Alexithymia Scale 20 [TAS-20]) to their psychiatric comorbidities, psychological symptoms/traits, SUD variables, and HRQoL. Results: Alexithymia was significantly higher in patients who had cannabis use disorder. Higher alexithymia scores were also related to higher levels of depression, anxiety, impulsivity, and lower HRQoL. After multivariate analysis, trait anxiety, impulsivity, and the physical component summary of the HRQoL were found to be independently related to alexithymia. Conclusions: SUD patients with higher alexithymia levels have more frequently psychiatric comorbidities, present specific psychological features, and have worse HRQoL. Hence, it is important to evaluate these factors and offer more accurate psychotherapeutic approaches for this patient population.
Article
Published version
English
Alexitímia; Diagnòstic dual; PSYCHIATRY AND PSYCHOLOGY::Behavior and Behavior Mechanisms::Behavior::Behavioral Symptoms::Affective Symptoms; DISEASES::Chemically-Induced Disorders::Substance-Related Disorders; Other subheadings::Other subheadings::Other subheadings::/complications; PSIQUIATRÍA Y PSICOLOGÍA::conducta y mecanismos de la conducta::conducta::síntomas conductuales::síntomas afectivos; ENFERMEDADES::trastornos inducidos químicamente::trastornos relacionados con sustancias; Otros calificadores::Otros calificadores::Otros calificadores::/complicaciones
Frontiers Media
Frontiers in Psychiatry;12
https://www.frontiersin.org/articles/10.3389/fpsyt.2021.659063/full
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - VHIR [1665]